Association Between Portal Flow Pulsatility and Right Ventricular Dysfunction in the Postoperative Period of Cardiac Surgery
NCT ID: NCT06777355
Last Updated: 2025-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2025-02-24
2025-07-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This dysfunction is associated with an increased risk of both renal and hepatic failure, complications that significantly affect patient outcomes. Doppler ultrasound has emerged as a valuable tool in predicting these complications, particularly in monitoring portal circulation and hepatic perfusion.
This study aims to explore the association between portal flow pulsatility and RVD after cardiac surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trans-thoracic Ultrasound VS Invasive Pressure of the Left Atrium
NCT03012308
Detection of Right Ventricular Dysfunction by Portal Vein Doppler After Cardiac Surgery
NCT04890860
Prognosis of Right Ventricular Dysfunction Assessed by Speckle Tracking in Postoperative Thoracic Surgery
NCT05060302
Continuous Monitoring of Right Ventricular Function, Based on the Correlation Between the C-X Segment of the Central Venous Pressure Curve, and the Echocardiographic Evaluation of Right Ventricular Systolic Function
NCT03295669
Strain Analysis for Assessment of Myocardic Dysfunction During Orthotopic Liver Transplantation
NCT05037838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Many studies have observed reduced right ventricular function intraoperatively through transthoracic echocardiographic parameters like TAPSE, fractional area change, and longitudinal strain. However, accurately assessing RVD is challenging, as these parameters can be affected post-surgery without indicating true ventricular failure.
In this context, obtaining reliable and robust invasive hemodynamic measurements is crucial for accurate assessment of RVD.
The pulmonary artery catheter (PAC), or Swan-Ganz catheter remains the gold standard, providing precise information on right ventricular systolic and diastolic function, pulmonary artery pressures, left ventricular end-diastolic pressure, venous oxygen saturation, and cardiac output.
In cardiac surgery, venous congestion resulting from right ventricular dysfunction is closely associated with increased mortality, leading to renal and hepatic failure. Tools like Doppler ultrasound (of renal, portal, and hepatic veins) can predict renal failure risk.
Researchers developed the VEXUS score in 2020 to assess this risk, and recent research found an association between 50% portal flow pulsatility and RVD.
However, some aspects remain to be clarified, such as the significant association between portal venous flow pulsatility and altered TAPSE.
This prospective study aims to examine the association between portal flow pulsatility and right ventricular dysfunction after cardiac surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transthoracic and Transesophageal echography within 24 hours post cardiac surgery
Measurement of portal flow velocity using transthoracic echography, as well as measurement of the superior vena cava via transesophageal echography for predicting right ventricular dysfunction.
Transthoracic and Transesophageal echography within 24 hours post cardiac surgery
Transthoracic and Transesophageal echography within 24 hours post cardiac surgery in patients at risk for postoperative complications
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transthoracic and Transesophageal echography within 24 hours post cardiac surgery
Transthoracic and Transesophageal echography within 24 hours post cardiac surgery in patients at risk for postoperative complications
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing cardiac surgery with cardiopulmonary bypass and presenting at least one risk factor for postoperative complications, including:
* Patient over 60 years old
* Preoperative left ventricular ejection fraction (LVEF) \< 50%
* Surgery involving both coronary artery bypass grafting and valve procedures
* Mitral valve surgery
* Preoperative creatinine clearance less than 30 ml/min
* Patient having signed the informed consent form in accordance with regulations
* Patient covered by social security or an equivalent healthcare system
Exclusion Criteria
* Tricuspid regurgitation greater than grade 2
* Known cirrhosis
* Patient with intrahepatic arteriovenous malformations
* Patient at risk for pulmonary artery catheter insertion:
* Tricuspid valve surgery
* Pacemaker or implantable cardioverter-defibrillator in place
* Patient with an esophageal tract abnormalities contraindicating transesophageal echocardiography (TEE)
* Pregnant or breastfeeding women
* Patient unable to understand the information provided
* Patient under guardianship, curatorship, or legal protection
* Patients deprived of liberty
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CMC Ambroise Paré
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CMC Ambroise Paré Hartmann
Neuilly-sur-Seine, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024/04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.